Loading clinical trials...
Loading clinical trials...
A Phase 1a/1b Multicenter, Open-label Dose Escalation/Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of PLN-101095 as Monotherapy and in Combination With Pembrolizumab in Adult Participants With Advanced or Metastatic Solid Tumors Who Have Disease Progression While on Pembrolizumab
Conditions
Interventions
PLN-101095
Pembrolizumab
Locations
5
United States
Yale University
New Haven, Connecticut, United States
South Texas Accelerated Research Therapeutics (START)
Grand Rapids, Michigan, United States
NEXT Austin
Austin, Texas, United States
University of Texas MD Anderson Cancer Center
Houston, Texas, United States
NEXT Virginia
Fairfax, Virginia, United States
Start Date
August 30, 2023
Primary Completion Date
June 1, 2025
Completion Date
December 1, 2025
Last Updated
June 12, 2024
NCT06716138
NCT06307795
NCT04585750
NCT05004116
NCT07213830
NCT05753722
Lead Sponsor
Pliant Therapeutics, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions